Cannabis Poland SA
WSE:CBD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.3315
0.729
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cannabis Poland SA
Cost of Revenue
Cannabis Poland SA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cannabis Poland SA
WSE:CBD
|
Cost of Revenue
-zł104.3k
|
CAGR 3-Years
-52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Molecure SA
WSE:MOC
|
Cost of Revenue
-zł1.6m
|
CAGR 3-Years
-156%
|
CAGR 5-Years
-62%
|
CAGR 10-Years
N/A
|
|
|
C
|
Celon Pharma SA
WSE:CLN
|
Cost of Revenue
-zł62.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Cannabis Poland SA
Glance View
Cannabis Poland SA engages in the production and distribution of cannabinoid vaporization equipment and oils. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2013-04-09. The firm focuses on operating in the field of production and sale of pharmaceutical and medical products, with the main focus on vaporization products containing cannabinoids manufactured from cannabis. The firm also expands its activity to include other products than pharmaceuticals, such as cosmetics, oils containing cannabinoids for human and animals and photovoltaic cells. The firm is engaged in research and development of a Cannabidiol (CBD)/ Tetrahydrocannabinol-based (THC-based) pharmaceutical for use in the treatment of seizures associated with drug-resistant epilepsy.
See Also
What is Cannabis Poland SA's Cost of Revenue?
Cost of Revenue
-104.3k
PLN
Based on the financial report for Dec 31, 2023, Cannabis Poland SA's Cost of Revenue amounts to -104.3k PLN.
What is Cannabis Poland SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-52%
Over the last year, the Cost of Revenue growth was 29%. The average annual Cost of Revenue growth rates for Cannabis Poland SA have been -52% over the past three years .
You don't have any saved screeners yet
